Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $43.
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $43.